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1. INTRODUCTION {#mbo3940-sec-0005}
===============

A recent report states that mortality associated with respiratory tract infections (RTIs) is the fifth‐leading cause of death overall (\"Global, regional, and national age‐sex specific all‐cause and cause‐specific mortality for 240 causes of death, 1990--2013: a systematic analysis for the Global Burden of Disease Study 2013,\" [2015](#mbo3940-bib-0009){ref-type="ref"}). In children less than 5 years old, the health effects are serious since nearly 1 million of these children died from RTIs in 2015 (Gao, Kang, Yu, & Ren, [2014](#mbo3940-bib-0008){ref-type="ref"}; Lelieveld, Haines, & Pozzer, [2018](#mbo3940-bib-0015){ref-type="ref"}). There are many causes of RTIS, mainly indoor and outdoor environmental pollution (Korzeniewski, Nitsch‐Osuch, Chciałowski, & Korsak, [2013](#mbo3940-bib-0013){ref-type="ref"}; Kovesi et al., [2006](#mbo3940-bib-0014){ref-type="ref"}), and RTIs are often accompanied by improper use of antibiotics (Schroeck et al., [2015](#mbo3940-bib-0025){ref-type="ref"}). In previous studies, it has been reported that the pharyngeal microbiome may have a protective function for RTIs. Microbial succession in the respiratory tract is determined in infancy and is linked to microbiota stability and respiratory health characteristics (Biesbroek et al., [2014](#mbo3940-bib-0001){ref-type="ref"}; Bosch et al., [2017](#mbo3940-bib-0002){ref-type="ref"}; Gao et al., [2014](#mbo3940-bib-0008){ref-type="ref"}). According to the Food and Agriculture Organization of the United Nations and the WHO, probiotics are live microorganisms which, when administered in adequate amounts, confer a health benefit on the host (Hill et al., [2014](#mbo3940-bib-0011){ref-type="ref"}), with the focus being mainly on the gut bacterial composition (Carolina Maldonado, Ivanna Novotny, Esteban, Alejandra de Moreno de, & Gabriela, [2015](#mbo3940-bib-0003){ref-type="ref"}; Didari, Mozaffari, Nikfar, & Abdollahi, [2015](#mbo3940-bib-0005){ref-type="ref"}; Martinez, Bedani, & Saad, [2015](#mbo3940-bib-0016){ref-type="ref"}; Quigley & Shanahan, [2014](#mbo3940-bib-0019){ref-type="ref"}). However, a role for probiotics in reducing nasal colonization by multidrug‐resistant bacteria (Warrack, Panjikar, Duster, & Safdar, [2014](#mbo3940-bib-0026){ref-type="ref"}) and respiratory tract infections (Gao et al., [2014](#mbo3940-bib-0008){ref-type="ref"}) has been proposed. For symbiotic microbiota of the upper respiratory tract, research has mainly focused on antagonistic strains against *Streptococcus pyogenes* (*S. pyogenes*) (Humphreys & McBain, [2019](#mbo3940-bib-0012){ref-type="ref"}) (Guglielmetti et al., [2010](#mbo3940-bib-0010){ref-type="ref"}), but also on *Streptococcus pneumoniae* (*S. pneumoniae*) (Roos, Hakansson, & Holm, [2001](#mbo3940-bib-0021){ref-type="ref"}) and *Staphylococcus aureus* (*S. aureus*) (Popova et al., [2012](#mbo3940-bib-0017){ref-type="ref"}).

In the present study, we analyzed the oropharyngeal microbiota in order to find probiotic strains that can antagonize pathogenic bacteria in healthy children.

2. MATERIALS AND METHODS {#mbo3940-sec-0006}
========================

2.1. Pathogenic bacterial strains {#mbo3940-sec-0007}
---------------------------------

The bacterial strains *S. aureus* (CICC 10201, China), *Escherichia coli* (*E. coli*) (CICC 10003, China), and *Pseudomonas aeruginosa* (*P. aeruginosa*) (CICC 20152, China) were purchased from the China Center of Industrial Culture Collection (CICC) and *Klebsiella pneumonia* (*K. pneumonia*) CGMCC 1.0839, *Proteus vulgaris* (*P. vulgaris*) CGMCC 1.1651, *Enterobacter cloacae* (*E. cloacae*) CGMCC 1.8726, and *Acinetobacter Baumannii* (*A. Baumannii*) CGMCC 1.10395 from the China General Microbiological Culture Collection Center. *S. pyogenes* is a clinical isolate found in our hospital.

2.2. Antagonistic bacterial strain collection {#mbo3940-sec-0008}
---------------------------------------------

Bacterial microbiota taken from the posterior pharyngeal walls of 5 healthy children (4--6 years old, Shenyang area) were collected at least 2 hr after meals using disposable sterile throat swab tubes (Chuangxin Medical Instrument Factory). After collection, the throat cotton swabs were placed in 1 ml of brain heart infusion (BHI) medium (BHI, Hopebio, China). After the suspension was diluted 1,000‐fold, 200 µl of bacterial solution was applied to a medium containing 15% sheep blood agar (Hopebio, China) and cultured at 37°C for 24 hr. Single colonies with green hemolytic rings were picked up with a sterile inoculating loop, streaked on 15% sheep blood agar medium, and cultured in an incubator at 37°C for 24 hr. As negative controls, swabs without throat contact but otherwise using the same protocol were used.

2.3. Screening of antagonistic bacterial strains for bacteriostatic effects on pathogenic bacteria {#mbo3940-sec-0009}
--------------------------------------------------------------------------------------------------

### 2.3.1. Primary screening {#mbo3940-sec-0010}

Single α‐hemolytic strains were isolated (about 300 strains from 5 pharyngeal swabs were detected in the initial screen), streaked on 15% sheep blood agar medium, and incubated at 37°C overnight. Then, a perforator (a sterile 1,000 μl pipette tip, Eppendorf) was used to perforate the cultured plate in order to obtain a bacterial cake with a diameter of about 8 mm. Then, the cakes were placed in nutrient agar medium coated with 200 µl of *S. aureus* (1 × 10^5^ cfu/ml) and cultured at 37°C for 24 hr to look for any *S. aureus* growth retardation.

### 2.3.2. Secondary screening {#mbo3940-sec-0011}

Colonies of the antagonistic strains were selected with a sterile inoculating loop, streaked onto 15% sheep blood agar medium plates, and incubated at 37°C overnight. Then, colonies from the entire plate were scraped off and dissolved in 800 µl of BHI medium after which 200 µl of bacterial suspensions (1--2 × 10^10^/ml) was placed in Oxford cups on a nutrient agar medium coated with 100 µl of pathogenic bacteria solutions (5--6 × 10^5^ cfu/ml) and cultured at 37°C for 24 hr to look for any bacteriostatic effects (Qian & Huang, [2000](#mbo3940-bib-0018){ref-type="ref"}).

### 2.3.3. Screening for antagonistic/pathogen bactericidal ratios {#mbo3940-sec-0012}

One hundred microliter of a pathogen stock solution (5--6 × 10^5^ cfu/ml) was mixed with 100 µl of an antagonistic strain stock solution (1--2 × 10^10^/ml) or 10, 100 and 1,000 fold dilutions, and streaked on a 15% sheep blood agar plate. α‐hemolytic antagonistic and β‐hemolytic pathogenic bacterial strains were then counted after 24 hr incubation at 37°C.

2.4. Identification of antagonistic strains {#mbo3940-sec-0013}
-------------------------------------------

Antagonistic strains were identified using mass spectrometry (MALDITOF MS, Vitek MS, BioMérieux, France) according to the manufacturer\'s instruction. 16S rDNA sequencing was performed with a bacterial 16S rDNA PCR Kit fast (800) (Takara, Japan) according to the manufacturer\'s protocol. Briefly, the colonies were selected and dissolved in 50 μl of sterile distilled water. After centrifugation at 8,000× *g* for 5 min, the supernatant was discarded and the pellets were dissolved in 50 μl of sterile distilled water again. After the subsequent addition of 50 μl 100 mM NaOH, the mixed suspension was heated at 95°C for 15 min. After adding 11 μl 1M Tris‐HCl (pH 7.0) and mixing, the suspension was centrifuged again and 2 μl supernatant was used for the PCR amplification of the bacterial 16S rDNA region, which consisted of 25 cycles at 94°C for 5 s, 55°C for 1 s and 68°C for 4 s in a ready to mix solution according to the manufacturer\'s instructions. After aliquots of the PCR products were analyzed with a 2% agarose gel (≈0.8 Kb), with a positive control (*E. coli* DNA) and a negative control without DNA, 100 ng DNA was sequenced with the sequencing primer 10F supplied with the kit (Sangon Biotech (Shanghai) Co., Ltd).

3. RESULTS {#mbo3940-sec-0014}
==========

First, the 300 α‐hemolytic bacterial colonies, collected from the initial screening on 15% sheep blood agar medium plates, were used for secondary screening using the Oxford cup method. As a result, 36 strains with growth inhibition effects on *S. aureus* were selected. Next, we used the Oxford cup method to determine the intensity of *S. aureus* growth inhibition of the 36 antagonistic strains. As a result, seven strains were selected, which produced *S. aureus* growth inhibition rings on the agar of \>10 mm (Table [1](#mbo3940-tbl-0001){ref-type="table"}).

###### 

Result of antibacterial diameter screening of 36 antagonistic respiratory probiotics derived from the first screening against *Staphylococcus aureus* (only strains with an inhibitory zone of \>10 mm were selected)

  Antagonistic bacterial strain number   1    2    3    4    5    6    7
  -------------------------------------- ---- ---- ---- ---- ---- ---- ----
  Bacteriostasis diameter (mm)           12   16   16   23   15   15   21

John Wiley & Sons, Ltd

Next, the growth inhibition of the seven screened antagonistic throat bacterial strains on *S. aureus*, *E. coli*, *P. aeruginosa,* and *S. pyogenes* was tested with the Oxford cup method, which led to the identification of four strains effective against the growth of the four pathogens (Figure [1](#mbo3940-fig-0001){ref-type="fig"}).

![Results of antibacterial Oxford cup analyses of antagonistic strains initially screened only for *S. aureus* against four common pathogenic bacteria. (a) Antagonistic activity against *S. aureus*, (b) Antagonistic activity against *E. coli*, (c) Antagonistic activity against *P. aeruginosa,* (d) Antagonistic activity against *S. pyogenes.* (Top: strain number: 1, left: strain number 2, bottom: strain number 4, right: strain number 7, middle: saline)](MBO3-8-e940-g001){#mbo3940-fig-0001}

MALDITOF MS and 16S rDNA analyses identified strain number 1 as *S. parasanguinis* with the closest 16S rDNA match to *S. mitis* NCTC 12,261 (pairwise similarity of 96.8%) further named *S. parasanguinis I;* strain number 2 as *S. mitis* with a pairwise 16S rDNA similarity of 99.21% to NCTC 12,261 (further named *S. mitis I*); strain number 4 as *S. mitis* with a pairwise 16S rDNA similarity of 96.42% to *S. dentisani* DSM 27,088 (further named *S. mitis II*); and strain number 7 as *S. parasanguinis* with a pairwise 16S rDNA similarity of 96.99% to NCTC 12,261 (further named *S. parasanguinis II*).

Determination of the optimum antibacterial concentration of antagonistic strains against four common pathogens (*S. aureus*, *E. coli*, *P. aeruginosa,* and *S. pyogenes*) revealed that antagonistic stock solutions (100 µl 1--2 × 10^9^) had the most bactericidal activity against the pathogenic bacteria (100 µl 5--6 × 10^4^), with decreasing efficacy when diluted 10 times (100 µl 1--2 × 10^8^), 100 times (100 µl 1--2 × 10^7^), and 1,000 times (100 µl 1--2 × 10^6^) (Table [2](#mbo3940-tbl-0002){ref-type="table"}).

###### 

Quantitative determination of effective bacterial ratios of four antagonistic strains against *Staphylococcus aureus*, *Escherichia coli,* and *"*+,−"indicates the resulting ratio of antagonistic strains to pathogens; *++++: ≥100:1, +++: \~10:1, ++: \~1:1, +: \~1:10, ±: ≤1:100,: none*

          *S. parasanguinis* I   *S. mitis* I    *S. mitis* II   *S. parasanguinis* II   *S. parasanguinis* I   *S. mitis* I   *S. mitis* II   *S. parasanguinis* II
  ------- ---------------------- --------------- --------------- ----------------------- ---------------------- -------------- --------------- -----------------------
          *S. aureus*            *E. coli*                                                                                                     
  x1      ++++                   ++++            ++++            ++++                    ++++                   ++++           ++++            ++++
  x10     ++                     ++              ++++            ++++                    ++                     ++             +++             +++
  x100    \+                     \+              +/−             \+                      \+                     \+             −               +++
  x1000   −                      −               −               +/−                     −                      −              −               +++
          *P. aeruginosa*        *S. pyogenes*                                                                                                 
  x1      ++++                   ++++            ++++            ++++                    +++                    ++++           ++++            +++
  x10     ++                     ++              +++             +++                     ++                     +++            ++              ++
  x100    \+                     \+              −               \+                      +/−                    \+             \+              \+
  x1000   \+                     −               −               −                       −                      −              −               −

John Wiley & Sons, Ltd

As evident in Table [3](#mbo3940-tbl-0003){ref-type="table"}, all four antagonistic strains had bacteriostatic effects on the common pathogens *S. aureus*, *P. aeruginosa*, *E. coli*, *K. pneumonia*, *P. vulgaris*, *E. cloacae, A. baumannii,* and *S. pyogenes.* In addition, bromcresol purple assays revealed that the mode of action was not mediated by lactic acid production (Figure [A1](#mbo3940-fig-0002){ref-type="fig"} in Appendix).

###### 

Determination of bactericidal effects of the 4 derived antagonistic strains against common pathogens

  Pathogens               *S. aureus*   *P. aeruginosa*   *E. coli*   *K. pneumoniae*   *P. vulgaris*   *E. cloacae*   *A. baumannii*   *S. pyogenes*
  ----------------------- ------------- ----------------- ----------- ----------------- --------------- -------------- ---------------- ---------------
  Antagonistic strains                                                                                                                  
  *S. parasanguinis* I    +++           ++                +++         ++                +++             ++             ++               ++
  *S. mitis* I            +++           ++                +++         ++                ++              ++             ++               +++
  *S. mitis* II           +++           ++                +++         ++                ++              ++             +++              ++
  *S. parasanguinis* II   +++           ++                +++         ++                ++              +++            +++              ++

+++, Bacteriostasis diameter ≥20 mm; ++, 15 mm ≤ Bacteriostasis diameter \<20 mm*.*

John Wiley & Sons, Ltd

4. DISCUSSION {#mbo3940-sec-0015}
=============

As result of screening in the present study, two *S. mitis* and two *S. parasanguinis* strains, derived from the oropharyngeal microbiota of five healthy children were isolated and showed antagonistic effects against *S. aureus*, *P. aeruginosa*, *E. coli*, *K. pneumonia*, *P. vulgaris*, *E. cloacae* and *A. baumannii,* and *S. pyogenes*. It has been suggested that in order to prevent respiratory tract infections microbiome homeostasis with beneficial species abundance should be maintained and that infections result from a disturbed balance between pathogenic expansion and microbiome homeostasis (Faden et al., [1997](#mbo3940-bib-0006){ref-type="ref"}; Gao et al., [2014](#mbo3940-bib-0008){ref-type="ref"}). Therefore, we suggest that the four antagonistic *Streptococcus* strains might lead to a balance between pathogens and probiotics in the respiratory tract, thereby preventing expansion of the pathogens and concomitant respiratory infections. In a previous study, administration of the *Streptococcus salivarius* K15 strain to children with recurrent oral streptococcal pathology reduced streptococcal pharyngeal infections and acute otitis media episodes (Di Pierro et al., [2012](#mbo3940-bib-0004){ref-type="ref"}). Other examples of probiotic treatment for limiting the overgrowth of potential pathogens include nasal sprays containing streptococci strains, and in previous trials, *S. mitis* has been shown to be beneficial for decreasing the recurrence rates of otitis media, tonsillitis or pharyngotonsillitis, and group A streptococci infections (Falck, Grahn‐Hakansson, Holm, Roos, & Lagergren, [1999](#mbo3940-bib-0007){ref-type="ref"}; Roos, Grahn, Holm, Johansson, & Lind, [1993](#mbo3940-bib-0020){ref-type="ref"}; Roos et al., [2001](#mbo3940-bib-0021){ref-type="ref"}; Roos, Holm, Grahn, & Lind, [1993](#mbo3940-bib-0022){ref-type="ref"}; Roos, Holm, Grahn‐Hakansson, & Lagergren, [1996](#mbo3940-bib-0023){ref-type="ref"}; Santagati et al., [2015](#mbo3940-bib-0024){ref-type="ref"}). However, whether one of the antagonistic *S. mitis* or *S. parasanguinis* strains from this study had similar effects needs to be further investigated.

5. CONCLUSIONS {#mbo3940-sec-0016}
==============

In this study, we isolated from the oropharyngeal microbiota of five healthy children two antagonistic *S. mitis* and one *S. parasanguinis* strain, which exhibited broad‐spectrum antagonistic activity against *S. aureus*, *P. aeruginosa*, *E. coli*, *K. pneumonia*, *P. vulgaris*, *E. cloacae, A. baumannii,* and *S. pyogenes*. We suggest that the growth of the mentioned streptococci strains may prevent pathogenic bacterial expansion.
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 {#mbo3940-sec-0023}

![Test for detection of lactic acid production with agar containing 0.04 g/L Bromcresol Purple (Cat No. 36408, Millipore). (a) Control agar plates without bacterial colonies at 18, 24 and 48 hr incubation. (b) *S. parasanguinis I*, *S. mitis I*, *S. mitis II,* and *S. parasanguinis II* after 18, 24, and 48 hr incubation. No lactic acid production took place](MBO3-8-e940-g002){#mbo3940-fig-0002}
